

## [Drug Injury Watch: Fall 2012: Two Recent Medical Reports Regarding Safety Of Pradaxa, Boehringer Ingelheim's Anticoagulation Drug](#)

### **Use Of Pradaxa After ACS Is Associated With Increased Rate Of Major Bleeding, And Concomitant Use Of Pradaxa With Multaq Is Contraindicated**

(Posted by Tom Lamb at [www.DrugInjuryWatch.com](http://www.DrugInjuryWatch.com) on September 26, 2012)

**SUMMARY:** First, Pradaxa is associated with increased rates of major bleeding when used to prevent thrombotic events after an acute coronary syndrome (ACS) according to a September 24, 2012 Archives of Internal Medicine article.

Second, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a new contraindication concerning the concomitant use of Multaq and Pradaxa.

[\[Read this article in full at original source\]](#)

***Earlier Pradaxa articles by Tom Lamb on the Drug Injury Watch blog:***

[Increasing Number Of Pradaxa Lawsuits Against Boehringer Are Consolidated In Federal Court MDL](#)

[Pradaxa Side Effects Update Mid-2012: Deaths, Hemorrhages, Acute Renal Failure, and Stroke Events Submitted To FDA MedWatch](#)

[Safety Developments Regarding Pradaxa: Boehringer Starts Drug Registry; EMA Wants Label Change; Study Compares Pradaxa Use To Coumadin As Regards Side Effects](#)

[Pradaxa Noted For Possible Heart Attack Risk In Addition To Serious Gastrointestinal Bleeding And Other Hemorrhages](#)

[Pradaxa Hemorrhage Cases May Occur In Oldest Patients Due To Age-Related Decline In Renal Function](#)

---

Attorney [Tom Lamb](#) represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.

<http://www.DrugInjuryWatch.com>